← Back to Search

SEL-212 low-dose for Gout (DISSOLVE II Trial)

Phase 3
Waitlist Available
Research Sponsored by Selecta Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

DISSOLVE II Trial Summary

This study is evaluating whether a drug may help reduce the size of tophi in individuals with gout.

Eligible Conditions
  • Gout

DISSOLVE II Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Serum uric acid control during Month 6
Secondary outcome measures
Gout Suppressants
Diabetes Insipidus
Percent reduction of mean serum acid
+5 more

DISSOLVE II Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: SEL-212 low-doseExperimental Treatment1 Intervention
IV infusion of SEL-212 low-dose every 28 days for a total of up to 6 infusions
Group II: SEL-212 high-doseExperimental Treatment1 Intervention
IV infusion of SEL-212 high-dose every 28 days for a total of up to 6 infusions
Group III: PlaceboPlacebo Group1 Intervention
IV infusion of Normal Saline every 28 days for a total of up to 6 infusions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SEL-212 high-dose
2020
Completed Phase 3
~270
SEL-212 low-dose
2020
Completed Phase 3
~270

Find a Location

Who is running the clinical trial?

Selecta Biosciences, Inc.Lead Sponsor
8 Previous Clinical Trials
679 Total Patients Enrolled
5 Trials studying Gout
519 Patients Enrolled for Gout
Swedish Orphan BiovitrumLead Sponsor
91 Previous Clinical Trials
12,061 Total Patients Enrolled
1 Trials studying Gout
112 Patients Enrolled for Gout
Medical DirectorStudy DirectorSelecta Biosciences, Inc.
2,772 Previous Clinical Trials
8,062,265 Total Patients Enrolled
12 Trials studying Gout
5,835 Patients Enrolled for Gout

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II
2020. "A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04596540.
~35 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top